IPA's earnings today. step is which couple call, I has thank in on last of be offer I afternoon, We're of years. IPA's and excited John solidified identity, accelerated forward which you inaugural welcome you, to in Thank Great. good the evolution major warm everyone. and for the in another call participating annual this a
and the everyone some begin I step with call would updates, provide to so are. take been, and goals a what where our sense we runway, of can have back future on we've a what accomplished, Before get routine like we
management those my of for half Jennifer IPA name emphasis may and I training Antibodies. who the CEO and about is molecular and I have cellular formal and to Dr. career meet, in pleasure also three an and Bath. joined industry represents years ago. about immunology So, manufacturing joining, had professional CMO, I President who latter in for my contract of have of formulation, ImmunoPrecise and the organization. stands testing disease. therapeutic development which infectious biology contract XX science part with years primarily. am manufacturing clinical are is the on development, experience I not My in preclinical spent of antibodies also a a that of discovery, and including contract And the manufacturing, decade research, and vaccines. space I CDMO working CRL, and the the
a world Danaher. During served biotechnology, have my acquired headquartered creation. Aldevron, Executive Dakota and which XX IPA, North who leading on value roles execution, Fargo, strategic CDMO, operations, the team being key also is to of Prior and years in and of planning in in the I I business on by midst performed was in experience
that of often that to evident treat and of that pushed technologies applied. the generation on working organizations pharma industry's diseases in new more biotech, points management effective all excessive find those most efficient closely contract comprehensive failed and solutions properly the and contract it pharma former of to boarded analytics had candidates Most and while organizations. in fail reasons may response, clinic the additional a compounding the to research burden avoided for challenges. during vendor management of incredibly career effective my R&D. been In that lack companies to too with was During the pool vendors consolidation, pain the across became had advanced clinic one identified the have And significant toward of products these that therapies diverse problems,
paradigms to XXXX ImmunoPrecise achievable. and came was the no but it industry not obviously February small vision right myself, the task. transformation is like believed And transforming because only market was Now that I of right the personnel, necessary, IPA in was leadership,
only objectives X.X at have remarkable transformational as a the for disrupt aggregate in and that technology up on antibody drug my past Our selection the vendor living what lead but on processes platform. discovery been multi traditional IPA industry, placed IPA simultaneously tenure, successful years to model, development our Over like the mission and candidate to everyday and journey. can in and the employees be IPA using have execution, has nothing, downstream executed described corporate our modernizing
same through to trajectory improving We taking against and assets our our only also treat the building have been to strong continued an clients, board technologies, IPA discovery as drive to mission and new this a elevate creation to growth range levels. designed of Since investors, but as of novel the engines IP to to commitment my and CEO, diseases. therapies IPS to value using to execute commitment IPA with wide has to over myself, ongoing CRL, a and development not
integrity trust scientists. we boundaries biologics discovery behind word, rigor, in our the to solid, We We position financial innovation. XXXX If expand growth. continues landscape, afraid strategically performance against stand our assess commitment -- the the this IPA further our our at scientific runway, company solid and push company's closely the in and technological monitor commitment the amazing has which to of for you of look aren't its a to and operational delivered and will clients
foundation our Our we believe and success many in years it the is the for works, recipe continued come. to
obviously compared and in employees. exactly to today ask position our tell, has IPA all efforts tireless team, can you we the where today. me outstanding And we I'd And an and not of have and class were even revenue to alternative we just be would are and accomplished. an Without are cutting you years traditional discovery As of class. or array can edge protein like antibody proud strong would of capabilities to that We say ago, I'm expanded possess all acknowledge of be that technologies ambitious base any really targeting fundamentally disease any formats broader IPAs X.X our deliver and I that stronger. to used recurring if biologics
pharma the functional, the compared to the fraction a have time efforts well companies propelled delivering of therapeutic of IPA in with vendor becoming Our for capability biotechnology a services to into characterized, as end-to-end produce candidates choice, and lead traditional methods. spotlight,
underpinned of support of display number combination any of with that building our the a delivery immunization such of species an ever selection, scFv. and including animal similar pipeline. antibodies is camelid phage as antibody which platform, Technologies, platform custom success a and traditional of to launch established meaningful our our development DeepDisplay B antibody new in technologies fact, antibodies or is growing XXXX, our clients In therapeutics transgenic antibodies from by cell formats, also enable libraries multiple our VHH the
In long-term leveraging our our which but only shareholders as are This years. listing the the as value our two them last experiences this know-how, the corporate we industry's and diversify two benefits value of our shareholder the in To the IPA continually core long-term owned markets our at its current pipeline we on invest investors, listing And clients, improve has not has global in major pronged IPA technologies assets. been exchange to end Importantly, across using been we creation, to institutional approach have that we're investments both and in fully our retail best XXXX unlocking focus come. these We the in-house tailored NASDAQ the shareholder is an future successful and believe now around furthering not are the allowed these NASDAQ needs, for goals year year year from the stock to of calendar ImmunoPrecise. acquisitions, point, just successfully with We've as has Fiscal has US, a subsequently the through achieved globe. been base but forward proprietary strategic and development, well to yet providing long-term R&D in IPA. as well. amazing dual IPA’s capabilities step company certainly XXXX. and developing
launch a a potent, antibodies antibodies diseases. work mature programs portfolios. dual and of assets which proof-of-concept year strategic proceeds subsets cancer vitro tumor TATX-XXX for including strengthens growing later candidates year. unique as closed TATX-XXX internal our targeting vivo as to neurodegenerative well by We've of of space, of successful our functional panel shareable achieve formats, Talem our details financing a in million. neurodegenerative on this calendar therapy finalize be of through further towards potential continued in different listing, in to characterization this highlighted sheet, balance with potential as our the the offering presence year analysis February flow goals We steady of of in diverse first-in-class the CRO candidate some this diseases. QX The non-clinical a is of model in with and programs. oncology in to enjoyed to raising highlight novel closed recently generate US$XX also antibody the ensuring of return of functional gross back investors, the public We preclinical runway IPA Following out-licensing our creating and followed intend and and of beginning a
the developing company antibodies cardiovascular that first-in-class, aims disease to target potential the for the TATX-XX, LDL, block announced the also We of by cardiovascular large best-in-class market. uptake antibody disease
a arteries. in targets more slides, the such, able LDL I'll currently begin That's that if manage lifecycle. in classes two nominating to candidates program the on are And potential and the the TATX-XXX milestones, We testing actually, immuno-oncology me Talem further them. such to with currently and TATX-XXX. to Thank identifying as the to keep determine exciting continue maturity target forever One development. We're plaque just as the transcytosis in of to focused The mechanisms laboratory unveiling for is who's want action of powerful to under we're which various reach are very distinct the you. and that be we anxious assets leads perfect. lead you prevent controlling preparing different to has two functional of via formation control whether
of both delta holding gamma vitro variants variants, non-clinical model, the in infection, of as Iota, screening. beta, a concern. alpha, IPA SARS-CoV-X well-established current therapies COVID More has have our XXX% program of has a these We've And of XXX% disease been therapy, to addressing potentially ownership across advancing and been our variants, well the including the about excited SARS-CoV-X the Eta, shown Kappa protection indications. as importantly, of and including tested variants all treatment multiple including efficacy in mono cocktail in and future concern and we're by SARS-CoV-X cocktail off all interest, to of animal and assets, means which revealed as variants as therapies of
strategy us rapid has Our our a cocktail platform efficacious it should and required. rationally been design enabled antibody reformulation to to designed sustained be for enable prediction
have Most on the recent globally. investor this vivo reach has markets of Strategically, advance have efficacy Our work support most IPA role pivotal available the to in remain needs synergistic experience continuously to is with for role get spike development. IPA we pharma to importantly, a beyond concerns so that why with cornering remain including in entitled have experiences past date, investment focused IPA enabled corporate protein to community me is Coronavirus evolving the institutional paper the be a the variants with and in to this investors human and outreach TATX-XX, our CROs direction that to message we functional large I of the out been on over awareness bio targeting played for scientific in with fully continue to published the to future. IPA an garnered which IPAs a received industry archive. our order year our my move to with as committed a cocktail CRO. about traditional toward SARS-CoV-X broadening ever multi-antibody financial We and of stage the that excited of informed grateful
onboard a cell and companies clients. platform for significantly at XXXX, revenue addressing fiscal company core market shift a a the engage This therapeutically potential. client business pivot program XX% our research therapeutic distribution in of development and optimized diagnostic with services CRO being value our institutions partners, XXXX from focused key therapeutic to Discovery to are a B unveiled majority In model. year higher of to of Our and conducted led past the
our making onboard Our remains of sticky. retention of therapeutic impressive, companies revenues extremely
have popularity. result, XX% a This a is in cell we is throughput rapid XXXX. stage workflow single to we've high since various characterization for in As the characteristics, frequently offering part relatively and immunization, and continues sequencing capabilities, the due related includes expertise. On requested preferred a enjoyed our implemented which identifying quick b CAGR technology grow most note, cell antibodies discovery early of to with B prime
due the antibody continue to this applicable broadly expect to platform. We this character of discovery
So certain target or to use limited not types. its species is
As our business acquired well technologies, very and of are we launch we several as integrated industry already companies company. listed other be this move and publicly forward strategy own one consolidation, and the To consolidators a massive with as successfully of since we've positioned then experiencing CROs effect, our to well.
company of you we but and to the not I But available won't cover want will help that some be the XXXX. to have I already, on all fiscal most encourage the future review all or important – If call believe SEDAR success. just in XXXX time, able filings year we ensure company's sec.gov. of done achievements do to highlight be our so able cover achievements, on IPAs fiscal highlights the accomplishments the interest to everyone cover In we to of of not won't
IPAs, We and out continue to CRM XXXX, on system. our rollout the of in ERP fiscal infrastructure. we year And global completed global build
Zymeworks and select second IP space, announced We our are generation cloning. advancing in a Twist and B stack, platform, and our will cell automation that have propel fiscal the Furthermore, selection year in and the the of its both subsequent of cell single increasing name technology partnership including developing innovation. efficiency Life X advanced deals during release Bioscience's, also to technology our with We've few. previously
development a hire, in for the formed We research optimization silico Mila, subsidiary, Institute in our engineer pipeline and X,XXX not sequencing completed using computer deep learning discuss in use than CoVAX design partnership and who good learning as to and to across approaches for World focused artificial optimizing protein recently antibody in a this our profit had antibody shored repertoire deep a times. access renowned learning we have provides enhance in-vitro payments next-generation the call for language. with Class Furthering have The of machine established and more globe. over also these intelligence at Research are book us payments His dedicated specialists as final world analyses silico into optimization. in connections Mila, with and specialists an and fiscal up We been to Lisa? to have depth platform, experienced We've tools while on acquisition, have to IPA efforts, deferred cited deep Lisa publication and work IPA's discovery AI but knowledge just financial learning has aided strategies selection. our well their immune partnership prediction is evaluating prior sharing innovative IPA’s and XXXX our financial – which integration depth and IPAs results, turning a segue to into and chapters
